BioSpace News Archive

Business

Statement from Mylan’s Board of Directors Regarding Retirement of CEO and Board Member Heather Bresch in Conjunction with the Combination of Mylan and Upjohn, a Division of Pfizer

Mylan’s Board of Directors shared the following statement regarding Heather Bresch’s retirement, which will be effective upon the closing of the combination of Mylan and Upjohn, a division of Pfizer.

July 29, 2019
·
10 min read
Drug Development

European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma

Opinion Granted Based on Significant Overall Survival Benefit for KEYTRUDA in Combination with Axitinib Compared to Sunitinib in Phase 3 KEYNOTE-426 Trial

July 29, 2019
·
33 min read
Business

Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine

Combines Mylan’s sustainable, diverse and differentiated portfolio of medicines with Upjohn’s trusted, iconic brands

July 29, 2019
·
22 min read
Deals

Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call to July 29, 2019 at 10:30 a.m. EDT

Pfizer’s second-quarter 2019 earnings conference call with investment analysts has been rescheduled for, July 29, 2019, at 10:30 a.m. EDT.

July 29, 2019
·
1 min read
Drug Development

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response (pCR) in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with Triple-Negative Breast Cancer (TNBC)

KEYTRUDA is the First Anti-PD-1 Therapy to Demonstrate a Statistically Significant Improvement in pCR Rates as Neoadjuvant Therapy for TNBC Regardless of PD-L1 Status

July 29, 2019
·
30 min read
Business

PFIZER REPORTS SECOND-QUARTER 2019 RESULTS

Pfizer Inc. reported financial results for second-quarter 2019 and updated certain components of its 2019 financial guidance.

July 29, 2019
·
52 min read
BioMidwest

Hillrom Introduces Next-Generation Breakthrough Technology In Fight Against Diabetic Retinopathy

New Welch Allyn® RetinaVue® 700 Imager Features Enhanced Security, 60° Degree Field of View and Completely Automated Retinal Image Acquisition in Pupils as Small as 2.5 Millimeters

July 29, 2019
·
3 min read
Deals

Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company

Exact Sciences Corp. and Genomic Health, Inc. announced that the companies have entered into a definitive agreement under which Exact Sciences will combine with Genomic Health for $72.00 per share in a cash and stock transaction valued at $2.8 billion.

July 29, 2019
·
18 min read
Policy

Soligenix Receives European Patents for Oral BDP in the Treatment of Acute Radiation Injury of the Gastrointestinal Tract

Patents cover SGX201 in acute radiation enteritis and OrbeShield® for acute total body irradiation

July 29, 2019
·
10 min read
Deals

Acerus to Report Second Quarter 2019 Financial Results and Host Investor Call

Acerus Pharmaceuticals Corporation will announce its second quarter 2019 financial and operating results on Wednesday, August 7, 2019 before the market opens.

July 29, 2019
·
1 min read